A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer
| 대상 질환 | Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer |
|---|---|
| 임상 단계 | 2상 |
| 스폰서 | Compass Therapeutics |
| 상태 | 완료 |
| 참여자 수 | 49 명 |
| 중재(약물) | CTX-009 |
| 시작일 | 2022년 12월 8일 |
| 완료일 | 2025년 5월 15일 |
| 결과 공개일 | 2026년 7월 28일 |
요약
This study is designed as an open-label, adaptive Simon Two-Stage study to evaluate the efficacy of CTX-009 in patients with metastatic colorectal cancer. A Simon Two-Stage adaptive design will enroll approximately 37 patients into Stage 1, and if criteria are met to move to Stage 2, an additional 47 patients will be enrolled.
Overall Response Rate
| CTX-009 10 mg/kg | 2 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- CryoBalloon Ablation for Treatment of Duodenal Adenomas — Johns Hopkins University
- Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refract — Jennerex Biotherapeutics
- Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III — National Cancer Institute (NCI)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps — National Cancer Institute (NCI)
- Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal — National Cancer Institute (NCI)
- Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating — National Cancer Institute (NCI)